Healrna Wins "Best Biotech Innovation Product Award" at 2025 Future Healthcare 100 Summit.

The 2025 VBEF Future Healthcare 100 Summit, themed "THE NOW·Tipping Point," was held at the Suzhou International Expo Center. During the event, the "Future Healthcare 100" list, jointly released by VB100, Arterial Network, and Eggshell Research Institute, was officially unveiled in Suzhou.

Healrna was awarded the "2025 Future Healthcare 100·Innovation Award—Best Biotech Innovation Product" for its groundbreaking achievements in veterinary mRNA vaccines. This marks the company’s second appearance on the prestigious list, following its previous win of the "Future Healthcare 100·Value Field Award." The recognition not only highlights HuiLiao Bio’s years of dedication to mRNA vaccine R&D but also serves as both an encouragement and a driving force for its future innovations.

This accolade reaffirms the company’s leadership in biotechnological advancements and its commitment to pushing the boundaries of medical science.

Launched in 2015, the Future Healthcare 100 ranking is China's first innovation-focused healthcare list targeting non-listed enterprises, jointly introduced by VB100, Arterial Network, and Eggshell Research Institute. It aims to identify and honor the most pioneering Chinese healthcare innovators who truly represent the future of medicine, uncover the core forces driving China's future healthcare industry, and accelerate innovation and transformation in the health sector.

After years of refinement and exploration, the "Future Healthcare 100 Series Rankings and Awards" evaluation system has grown increasingly comprehensive. It has expanded into a global, multi-dimensional healthcare innovation ecosystem assessment, covering enterprises, investment institutions, medical organizations, industrial parks, and more. Recognized as one of the most authoritative evaluation systems in China's healthcare innovation sector, it continues to set benchmarks for excellence in medical and health innovation.

At the 2025 VBEF Top 100 Awards Product Launch Event, Dr. Chen Zhong, Vice President of Healrna, elaborated on the technical barriers in mRNA drug development and presented the company's breakthrough progress in veterinary mRNA vaccine R&D.

Healrna's self-developed PEDV mRNA vaccine for animals currently leads global development efforts. Equipped with the company's proprietary mRNA vaccine delivery system, the vaccine exhibits enhanced physicochemical stability and superior efficacy in challenge-protection trials. This innovation comprehensively addresses multiple bottleneck issues currently hindering mRNA vaccine development worldwide.

The achievement underscores Healrna's pioneering role in overcoming critical technical hurdles and advancing mRNA technology for veterinary applications.

mRNA technology shines as a beacon in life sciences – those meticulously validated sequences in laboratories, those rigorously scrutinized clinical data, represent scientists' relentless pursuit to decipher the code of life with scientific precision.

We understand that every base precisely edited, every nanoparticle optimally delivered redefines the boundaries of traditional vaccines. Holding this technology as our torch, we remain committed to advancing mRNA vaccines for animal health and human infectious disease prevention, transforming what were once "untreatable" challenges into hopeful possibilities with "tangible solutions."

Through persistent innovation, we strive to turn scientific breakthroughs into real-world protections, bringing light where medical darkness once prevailed.

#About Healrna #

Healrna is a high-tech enterprise engaged in the comprehensive provision of nucleic acid drug industrialization. The company's business spans the research and production of mRNA drugs, clinical trial design, data analysis, and other areas, with a focus on the development of mRNA technology-based infectious disease vaccines, cancer vaccines, cell therapies, protein replacements, and more.